JCO Precision Oncology · Nov 2, 2026
Redefining the EPCAM Phenotype: Deletion Architecture Determines Lynch Syndrome Cancer Risk
By Kohler K, Marsh APL, Hernandez F et al.
Purpose: To characterize the cancer phenotype and clinical presentation across molecularly distinct EPCAM deletion subgroups and determine how the phenotype varies with MSH2 involvement. Methods: We retrospectively evaluated 662 unrelated probands undergoing hereditary cancer multigene panel testing (MGPT) with isolated EPCAM full-gene deletions (n = 22), isolated EPCAM 3' deletions (n = 96), contiguous EPCAM full-gene deletions extending into MSH2 (n = 64), contiguous EPCAM 3' deletions extending into MSH2 (n = 116), MSH2 gross deletions (n = 155), and MSH2 nonsense/frameshift (ns/fs) variants (n = 209). Lynch syndrome (LS)–associated cancer prevalence, tumor spectrum, and PREMM5 scores were compared across cohorts. Multivariable logistic regression estimated cancer-specific associations relative to a MGPT-negative reference cohort. Results: Isolated EPCAM full-gene deletions, comprising 18.6% of observed isolated EPCAM deletions, were not significantly associated with LS-associated cancers. The LS-associated cancer prevalence was 13.6% in this cohort, compared with 54.6% with isolated EPCAM 3' deletions and 64.1%-72.2% in MSH2 -involving cohorts ( P < .001). Relative to MGPT-negative individuals, isolated EPCAM 3' deletions were strongly associated with colorectal cancer (odds ratio [OR], 17.59; P < .001) but not endometrial cancer (OR, 0.76; P = .790). MSH2 -involving cohorts demonstrated strong associations with both colorectal (ORs, 8.50-16.03; P < .001) and endometrial cancers (ORs, 17.31-30.47; P < .001). Conclusion: These findings provide new insights into the molecular and clinical heterogeneity of germline deletions involving EPCAM . Expanded detection across the full EPCAM gene and its 3' region distinguishes isolated full-gene deletions, which do not disrupt downstream MSH2 and are not associated with LS phenotypes, from isolated 3' deletions with a colorectal-predominant phenotype, and contiguous EPCAM-MSH2 deletions with an MSH2 -like LS phenotype. Precise delineation of EPCAM deletion boundaries and MSH2 involvement define three clinically relevant risk groups and support more precise risk assessment, counseling, and surveillance.
doi.org/10.1200/po-26-00974Open accessPubMed 42970717Populations